The NIA Interventions Testing Program represents a multi-site translational research program to evaluate agents hypothesized to extend mouse lifespan by retardation of aging or postponement of late life diseases. Interventions proposed by multiple collaborating scientists from the research community are initially tested, in parallel, at three sites (Jackson Laboratories, Michigan and Texas), using identical, standardized protocols, and using sufficient numbers of genetically heterogeneous mice to provide 80% power for detecting changes in lifespan of 10%, for either sex, after pooling data from any two of the test sites. Forty such lifespan experiments, involving various doses of 25 distinct agents, have been initiated in the first nine years of the ITP. Significant effects on longevity, in one or both sexe, have been documented for 5 of the tested agents: aspirin, NDGA, rapamycin, acarbose, and 17-?-estradiol. Initial lifespan trials are now underway for 8 agents, as well as comprehensive analyses of the effects of rapamycin, acarbose, and NDGA on health and on cellular and physiological traits thought likely to mediate the beneficial effects seen. Plans for the next five year period include additional lifespan (""""""""Stage I"""""""") trials, detailed analyses (""""""""Stage II"""""""") of agent found to increase lifespan, and increased emphasis on collaborations with other scientists skilled at evaluating traits related to health and disease or at testing ideas about mechanisms of drug action on aging. Each of the three ITP laboratories will bring special expertise to the effort measures of age-sensitive traits at the Jackson Laboratory, pathology and statistical analysis at Michigan, and pharmacology at the University of Texas.

Public Health Relevance

The NIA Interventions Testing Program represents a multi-site translational research program to evaluate agents hypothesized to extend mouse lifespan by retardation of aging or postponement of late life diseases. If successful, the work of the ITP consortium and its collaborators will lead to two kinds of progress: 1) it will yield new insights into the control of aging, aging rate, and age-associated diseases, and generate new mouse models to support work on these topics throughout the scientific community;and 2) it may help to facilitate the eventual development of agents that could be of benefit in preventive medicine, either by disrupting links between aging and disease, or by retardation of multiple diseases through decelerating the aging process itself.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-2 (M2))
Program Officer
Fuldner, Rebecca A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center
Schools of Medicine
San Antonio
United States
Zip Code
Hook, Michael; Roy, Suheeta; Williams, Evan G et al. (2018) Genetic cartography of longevity in humans and mice: Current landscape and horizons. Biochim Biophys Acta Mol Basis Dis 1864:2718-2732
Weiss, Roxanne; Fernandez, Elizabeth; Liu, Yuhong et al. (2018) Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. Aging (Albany NY) :
Nadon, Nancy L; Strong, Randy; Miller, Richard A et al. (2017) NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model. EBioMedicine 21:3-4
Siegmund, Stephanie E; Yang, Hua; Sharma, Rohit et al. (2017) Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. Hum Mol Genet 26:4588-4605
Dodds, Sherry G; Livi, Carolina B; Parihar, Manish et al. (2016) Adaptations to chronic rapamycin in mice. Pathobiol Aging Age Relat Dis 6:31688
Richardson, Arlan; Fischer, Kathleen E; Speakman, John R et al. (2016) Measures of Healthspan as Indices of Aging in Mice-A Recommendation. J Gerontol A Biol Sci Med Sci 71:427-30
Strong, Randy; Miller, Richard A; Antebi, Adam et al. (2016) Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an ?-glucosidase inhibitor or a Nrf2-inducer. Aging Cell 15:872-84
Tardif, Suzette; Ross, Corinna; Bergman, Phillip et al. (2015) Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci 70:577-87
Ross, Corinna; Salmon, Adam; Strong, Randy et al. (2015) Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY) 7:964-73
Bai, Xiang; Wey, Margaret Chia-Ying; Fernandez, Elizabeth et al. (2015) Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis 5:28743

Showing the most recent 10 out of 25 publications